Cardiovascular system changes in rheumatoid arthritis patients with continued low disease activity

Rheumatology International
Małgorzata BiskupBożena Targońska-Stepniak

Abstract

Systemic inflammation and disease activity seem to contribute to excessive prevalence of cardiovascular (CV) diseases (CVDs) in patients with rheumatoid arthritis (RA). The objective of the study was to assess chosen CV parameters in RA patients who have continuous low disease activity. The study group consisted of 70 RA patients without known CVD and 33 healthy controls, of a comparable age. All RA patients had continued low disease activity (DAS28 ≤ 3.2) from 2 to 7 years. The groups were assessed for: blood pressure, serum amino-terminal pro-brain natriuretic peptide (NT-proBNP), carotid intima media thickness (cIMT), electrocardiography (ECG), ejection fraction (EJ) and diastolic dysfunction (E/A ratio) in echocardiography. In RA patients in comparison with controls, significantly greater values of cIMT [0.83 (0.21) vs 0.62 (0.1) mm, p < 0.001] were found, as well as higher incidence of atherosclerotic plaques [43 (61.4%) vs 10 (30.3%), p = 0.003], prolonged QTc interval [439.6 (23.7) vs 414.0 (27.9) ms, p < 0.001]. High or very high Systemic Coronary Risk Evaluation (SCORE) was found in 32.9% of patients with RA and increased serum NT-proBNP in 71.4%. The mean values of CV parameters (cIMT, E/A, NT-proBNP, SCORE) were asso...Continue Reading

References

Sep 18, 2009·Current Vascular Pharmacology·Armen Yuri GasparyanGeorge D Kitas
May 26, 2010·Annals of the Rheumatic Diseases·Kimberly P LiangSherine E Gabriel
Jul 23, 2011·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Bożena Targońska-StepniakMaria Majdan
Sep 25, 2012·Arthritis Care & Research·Fawad AslamMahboob Alam
May 31, 2014·Autoimmunity Reviews·Pietro Enea LazzeriniFranco Laghi-Pasini
Feb 27, 2015·Thrombosis and Haemostasis·Pasquale AmbrosinoMatteo Nicola Dario Di Minno
Jul 1, 2015·Clinical Rheumatology·Pooneh DehghanAfshin Mohammad Alizadeh
Aug 22, 2017·World Journal of Cardiology·Sherry MasoudVasileios Panoulas

❮ Previous
Next ❯

Citations

Mar 5, 2019·Heart Failure Reviews·Sophie I MavrogeniGenovefa Kolovou
May 18, 2019·International Journal of Rheumatic Diseases·Hiroko YamamotoYasutomo Fujii
Apr 30, 2019·BioMed Research International·Bożena Targońska-StępniakMaria Majdan
Dec 13, 2018·Clinical Rheumatology·Bożena Targońska-StępniakMaria Majdan
Oct 8, 2020·International Journal of Rheumatic Diseases·Ender Özgün ÇakmakMehmet Engin Tezcan
Sep 14, 2020·Joint, Bone, Spine : Revue Du Rhumatisme·Romain BordyPerle Totoson

❮ Previous
Next ❯

Methods Mentioned

BETA
ESR
enzyme-linked immunosorbent assays
ELISA

Software Mentioned

mSCORE
ASPEL

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.